Susquehanna International Group, LLP Hookipa Pharma Inc. Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$0.59 - $1.04 $75,905 - $133,799	-128,653 Reduced 71.75%	50,642 $29,000
Q1 2024 May 07, 2024	BUY	$0.61 - $0.83 $109,369 - $148,814	179,295 New	179,295 $127,000
Q4 2022 Feb 14, 2023	BUY	$0.73 - $14.6 $19,381 - $387,630	26,550 Added 143.79%	45,014 $36,000
Q3 2022 Nov 14, 2022	BUY	$1.27 - $15.0 $6,671 - $78,795	5,253 Added 39.76%	18,464 $25,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.31 $5,809 - $10,090	-4,368 Reduced 24.85%	13,211 $22,000
Q4 2021 Feb 14, 2022	SELL	$2.33 - $5.94 $45,281 - $115,437	-19,434 Reduced 52.51%	17,579 $41,000
Q3 2021 Nov 15, 2021	SELL	$5.89 - $9.35 $173,319 - $275,133	-29,426 Reduced 44.29%	37,013 $218,000
Q2 2021 Aug 11, 2021	BUY	$9.16 - $19.51 $220,737 - $470,151	24,098 Added 56.91%	66,439 $609,000
Q1 2021 May 17, 2021	BUY	$10.64 - $14.7 $200,787 - $277,403	18,871 Added 80.4%	42,341 $569,000
Q4 2020 Feb 16, 2021	BUY	$9.32 - $13.63 $122,949 - $179,806	13,192 Added 128.35%	23,470 $260,000
Q3 2020 Nov 16, 2020	BUY	$8.59 - $11.89 $88,288 - $122,205	10,278 New	10,278 $97,000

677K

Ticker HOOK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,654,500
Market Cap $155M
Description
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transpl...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.